This morning, the Federal Circuit released a precedential opinion in a patent case appealed from the District of Delaware and a nonprecedential opinion in another patent case appealed from the Southern District of California. The Federal Circuit also released an errata in a patent case decided in late July and a nonprecedential order dismissing an appeal. Here are the introductions to the opinions and links to the errata and dismissal.
Laboratory Corporation of America Holdings v. Qiagen Sciences, LLC (Precedential)
Qiagen Sciences, LLC and others (collectively “Qiagen”) appeal from a final judgment of the United States District Court for the District of Delaware following a jury trial. The jury awarded Laboratory Corporation of America Holdings, Labcorp Genetics, Inc., and The General Hospital Corporation (collectively, “Appellees”)2 damages for infringement of its U.S. Patent 10,017,810 (“the ’810 patent”) and U.S. Patent 10,450,597 (“the ’597 patent”). See J.A. 73–77. After trial, the district court denied Qiagen’s renewed motion for judgment as a matter of law. ArcherDX, LLC v. Qiagen Scis., LLC, No. 18-cv-1019, 2022 WL 4597877 (D. Del. Sep. 30, 2022) (“Decision”). Qiagen timely appealed and, as explained below, we reverse.
Taction Technology, Inc. v. Apple Inc. (Nonprecedential)
Taction Technology, Inc. (Taction) appeals the United States District Court for the Southern District of California’s grant of summary judgment of noninfringement of claims 1–20 of U.S. Patent No. 10,659,885 and claims 1–17 of U.S. Patent No. 10,820,117 (asserted claims). For the following reasons, we vacate and remand for further proceedings.